A Japanese drug giant and a tiny New York biotech are teaming up in an unprecedented way


In drug development, the typical trajectory for a small biotech company is to develop a drug, then find a big-pharma partner to help fund trials and get the drug onto the market if it gets approved. Japan's Takeda Pharmaceuticals is teaming up with New York-based biotech company Ovid Therapeutics to co-develop TAK-935, a drug meant to treat rare epilepsy disorders in children.



from Biotech News